Association of Serum 25-Hydroxyvitamin D with Lifestyle Factors and Metabolic and Cardiovascular Disease Markers: Population-Based Cross-Sectional Study (FIN-D2D)

Maija E. Miettinen1–14, Leena Kinnunen1, Jaana Leiviskä2, Sirkka Keinänen-Kiukaanniemi3,4, Eeva Korpi-Hyöväli5, Leo Niskanen6,7, Heikki Oksa8, Timo Saaristo9,10, Jaakko Tuomilehto1,5,11,12, Mauno Vanhala7,13, Matti Uusitupa14,15, Markku Peltonen16

1 Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland, 2 Disease Risk Unit, National Institute for Health and Welfare, Helsinki, Finland, 3 Institute of Health Sciences, University of Oulu, Oulu, Finland, 4 Unit of Primary Health Care, Oulu University Hospital, Oulu, Finland, 5 Department of Internal Medicine, South Ostrobothnia Central Hospital, Seinäjoki, Finland, 6 Finnish Medicines Agency, Helsinki, Finland, 7 Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland, 8 Tampere University Hospital, Tampere, Finland, 9 Pirkanmaa Hospital District, Tampere, Finland, 10 Finnish Diabetes Association, Tampere, Finland, 11 Center for Vascular Prevention, Danube-University Krems, Krems, Austria, 12 King Abdulaziz University, Jeddah, Saudi Arabia, 13 Primary Health Care Unit, Central Finland Central Hospital, Jyväskylä, Finland, 14 Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, 15 Research Unit, Kuopio University Hospital, Kuopio, Finland, 16 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland

Abstract

Objectives: Low serum 25-hydroxyvitamin D (25OHD) level has been associated with an increased risk of several chronic diseases. Our aim was to determine lifestyle and clinical factors that are associated with 25OHD level and to investigate connection of 25OHD level with metabolic and cardiovascular disease markers.

Design: In total, 2868 Finnish men and women aged 45–74 years participated in FIN-D2D population-based health survey in 2007. Participants that had a serum sample available (98.4%; n = 2822) were included in this study. 25OHD was measured with chemiluminescent microparticle immunoassay method.

Results: The mean 25OHD level was 58.2 nmol/l in men (n = 1348) and 57.1 nmol/l in women (n = 1474). Mean 25OHD level was lower in the younger age groups than in the older ones (p<0.0001 both in men and women). This study confirmed that low physical activity (p<0.0001 both in men and women), smoking (p = 0.0002 in men and p = 0.03 in women) and high BMI (p<0.0001 in women) are factors that independently associate with low 25OHD level. Of the metabolic and cardiovascular disease markers high triglyceride concentration (p = 0.02 in men and p = 0.001 in women) and high apolipoprotein B/apolipoprotein A1 ratio (p = 0.04 in men and p = 0.03 in women) were independently associated with low 25OHD level.

Conclusions: Higher age did not predict lower 25OHD level in this study population of aged 45–74 years which may derive from a healthy life-style of “active pensioners”. Low physical activity and smoking came up as independent lifestyle factors associated with low 25OHD level. Defining the molecular mechanisms behind the associations of 25OHD with low physical activity and smoking are important objective in future studies. The association of 25OHD with BMI, high triglyceride concentration and apolipoprotein B/apolipoprotein A1 ratio may be related to the role of vitamin D in inflammation, but more detailed studies are needed.

Introduction

Low serum 25-hydroxyvitamin D [25OHD] level has been associated with several diseases including cancer, type 2 diabetes, osteoporosis, autoimmune diseases, cardiovascular diseases and schizophrenia [1]. Vitamin D is naturally synthesized from 7-dehydrocholesterol by the skin’s exposure to ultraviolet B radiation. The best estimate of an individual’s vitamin D status is the measurement of circulating vitamin D, 25OHD [1], which provides an indication of vitamin D stores obtained from both UV-light and dietary intake. Dietary sources of Vitamin D include fatty fish and fortified...
foods like milk and margarine. At the time of sample collection of the present study (year 2007) fish was the most important dietary source of vitamin D for both sexes among Finns aged 25–64 years [2]. Vitamin D is first hydroxylated in the liver to 25OHD and again in the kidney to form the biologically active 1,25-dihydroxyvitamin D. Low 25OHD level may be a result of inadequate sun exposure, deficient consumption of vitamin D-rich products or malabsorption of vitamin D [3].

25OHD concentration of 25 nmol/l has traditionally been considered as a boundary for vitamin D deficiency [4,5]. However, in recent years several experts have suggested a cut-off level of 50 nmol/l for vitamin D deficiency [1,6]. Concentration of 75 nmol/l or higher has been suggested as an optimal 25OHD level [6]. However, a reverse J-shaped association between 25OHD level and all-cause mortality has been suggested in the NHANES study [7].

In traditionally living indigenous populations in East Africa the mean 25OHD level in adult population has been shown to be 115 nmol/l [8]. There is no consensus about the toxic 25OHD concentration, but 375–500 nmol/l and higher than 600 nmol/l have been suggested [9,10].

A combination of increased triglyceride-rich very low-density lipoproteins and small, dense low-density lipoproteins (LDL) and decreased high-density lipoproteins (HDL) is a common feature in metabolic syndrome (MetS) [11,12]. Apolipoprotein A1 (apoA1) is the main protein in HDL particles and apolipoprotein B (apoB) in all the other lipoproteins [13,14]. ApoB/apoA1 ratio combines the atherogenic and antiatherogenic lipoproteins and an elevated apoB/apoA1 ratio has been connected to MetS [15]. ApoB/apoA1 ratio has also been shown to be a good predictor of cardiovascular disease and atherosclerosis [15–19], and it has been suggested that ApoB/apoA1 ratio should be used instead of cholesterol concentrations as a risk marker of myocardial infarction [17]. Several studies have found an association between low 25OHD level and MetS [20,21], but little is known of the link between 25OHD level and different components of the lipid disorders related to MetS, like elevated triglyceride and apoB concentrations and an increased apoB/apoA1 ratio.

Our aim was to determine the lifestyle and clinical factors that are associated with 25OHD level and to investigate connection of 25OHD level with metabolic and cardiovascular disease markers. We found several factors associated with 25OHD level that should be considered when investigating the role of vitamin D in different diseases.

Materials and Methods

Subjects

This study is a part of the FIN-D2D health survey 2007, which is a joint project within the Finnish National Diabetes Prevention program FIN-D2D [22,23]. Initially, a random sample of 4500 people aged 45–74 years, stratified according to gender, 10-year age groups (45–54, 55–64, and 65–74 years), and geographical areas (Hospital Districts of Pirkannaa, Central Finland and South Ostrobothnia), was selected from the National Population Register in August 2007. Sample size of the population where this cohort was extracted in 2007 was 34936. The study participants were invited by mail to a health examination. The participants attended a health examination carried out by a trained nurse according to the multinational monitoring of trends and determinants in cardiovascular disease (MONICA) protocol. A total of 2868 persons (64%) participated in the health examination during October, November and December in 2007. Of these persons those that had a serum sample available were included in the present study (98.4%; n = 2822). All participants signed an informed consent form. Ethical committee of the Hospital District of Helsinki and the Uusimaa approved the study.

Waist circumference, triglycerides, HDL cholesterol, blood pressure and fasting plasma glucose were used to define the presence of metabolic syndrome according to the International Diabetes Federation 2009 criteria [24]. Information on glucose tolerance status during 2 hour oral glucose tolerance test together with reported drug-treated type 2 diabetes was used to indicate presence of normal glucose regulation (NGR), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), screen-detected type 2 diabetes (SDM) or type 2 diabetes according to the WHO 1999 diagnostic criteria [25]. Participant’s cardiovascular risk was estimated with the Framingham [26] risk score, and with the apoB/apoA1 ratio.

Methods

Height was measured to the nearest 0.1 cm. Weight was measured in light clothing. Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m). Waist circumference was measured midway between the lower rib margin and the iliac crest. Serum triglycerides, HDL cholesterol, and plasma glucose were measured by enzymatic methods with Abbott Architect analyzer (Abbott Laboratories, Abbott Park, IL, USA). ApoA1 and apoB were measured with immunoturbidimetric methods and high sensitivity C-reactive protein (hs-CRP) was measured with ultrasensitive immunoturbidimetric method using Abbott Architect reagents. The inter-assay coefficients of variation (CV) for triglycerides, HDL cholesterol, and glucose were 1.2%, 2.5%, and 1.4%, respectively. CVs for apoA1, apoB, and hs-CRP were 1.3%, 2.5% and 2.9%, respectively.

Data of education and total household income were used as indicators of the socio-economic status. Educational level was divided into groups according to years of completed education: low (0–9 years), medium (10–12 years) and high education (13 years or more). Total household income per year was reported in three categories: low (<30 000 €/year), medium (30 001–60 000 €/year) and high (60 001–80 000 or more €/year).

Vitamin D analyses

The serum samples were collected during the end of year 2007 within three months (October–December). The samples were stored frozen in −20°C until analysis (4 years). 25OHD was determined by chemiluminescent microparticle immunoassay by Architect i system (Abbott Laboratories, Abbott Park, IL, USA). The interassay CVs of 25OHD were 6.7% and 3.8% at the levels of 34 nmol/l and 102 nmol/l, respectively. The bias compared to all-laboratory trimmed mean in the Vitamin D International External Quality Assessment Scheme (DEQAS) was −6.4%±7.1 (mean ± SD). 25OHD concentration lower than 50 nmol/l was considered as vitamin D deficiency, between 50 nmol/l and 75 nmol/l as vitamin D sufficiency and higher than 75 nmol/l as an optimal 25OHD level.

Statistical analyses

Descriptive statistics (means, standard deviations and proportions) were used to describe the study population. Age- and gender-specific 25OHD levels were calculated among the participants by lifestyle factors and cardiovascular disease markers. In these analyses, continuous variables were categorized in order to evaluate linearity in associations. Univariate comparisons between groups were evaluated by the chi-square test or logistic regression models. Analysis of covariance (ANCOVA) and logistic regression models were further used to evaluate the associations between
25OHD concentrations and lifestyle factors and metabolic disease markers adjusting for possible confounding factors. The possible confounding factors were pre-determined and included age, gender, BMI, month of sample collection, physical activity and smoking. Assumptions of the ANCOVA models were evaluated by graphical methods. The goodness of fit in logistic regression models was assessed with the Hosmer-Lemeshow test. No interaction terms were included in the models. Statistical analyses were carried out using the Stata statistical package 10.1 (StataCorp LP).

Results

Characteristics of the study subjects are shown in table 1. Information on age, month of sample collection, use of vitamin D supplements, HDL concentration, triglyceride concentration, fasting glucose, hs-CRP and apoB/apoA1 ratio (men) was available from 100% of the participants. Information on physical activity, smoking, education, waist circumference, blood pressure, Framingham score, and apoB/apoA1 ratio (women) was available from >95% of the participants. Information on household income and on use of hormone replacement therapy was available from >90% of the participants. The main reason for the missing information was that the participants did not answer all questions in the questionnaire included in the study.

25OHD level and its relation to lifestyle and related factors

The results of the univariate analysis of the 25OHD level in men and women are presented in Table 2. Higher 25OHD level was associated with higher age (men \( p < 0.0001 \); women \( p < 0.0001 \)). Month of sample collection was associated with 25OHD, the mean level being approximately 8% higher in samples collected during October than during November and December (men \( p < 0.0001 \); women \( p = 0.001 \)). Higher BMI was associated with lower 25OHD level (men \( p = 0.04 \); women \( p < 0.0001 \)). Only 1.5% (\( n = 20 \)) of the men and 3.1% (\( n = 46 \)) of the women had BMI lower than 20 and thus a meaningful analysis of this group separately was not possible. Low physical activity was associated with lower 25OHD level (men \( p < 0.0001 \); women \( p < 0.0001 \)). Participants that did not use vitamin containing supplements had lower 25OHD level than those using supplements (men \( p < 0.0001 \); women \( p < 0.0001 \)). Smokers had lower 25OHD level than the non-smokers (men \( p < 0.0001 \); women \( p = 0.002 \)). Use of hormone replacement therapy and absence of menstruation was associated with higher 25OHD level (\( p = 0.02 \) and 0.002, respectively). No association was seen between educational level and total household income with 25OHD level.

Statistically significant association of 25OHD level with age (in men and women \( p < 0.0001 \)), month of sample collection (in men \( p < 0.0001 \); in women \( p = 0.002 \)), physical activity (in men and in women \( p < 0.0001 \)), use of vitamin D supplements (in men and in women \( p < 0.0001 \)) and smoking (in men \( p = 0.0002 \); in women \( p = 0.002 \)) remained in the multivariate model when adjusted for age, gender, BMI, month of sample collection, physical activity and smoking (table 2). The association of 25OHD with BMI remained significant only in women (\( p < 0.0001 \)). Use of hormone replacement therapy and presence of menstruation were not associated with 25OHD level in the multivariate model.

The proportion of men and women with 25OHD deficiency (< 50 nmol/l), sufficiency (50–75 nmol/l) and with an optimal 25OHD level (>75 nmol/l) was calculated. Of men 30.6% had vitamin D deficiency, 54.0% a sufficient and 15.4% an optimal 25OHD level. Of women 36.0% had vitamin D deficiency, 49.5% a sufficient and 14.5% an optimal 25OHD level. Vitamin D deficiency was more common among women than men (\( p = 0.01 \)). Only 1% (\( n = 13 \)) of the men and 0.7% (\( n = 10 \)) of the women had severe vitamin D deficiency (25OHD < 25 nmol/l). Prevalence of vitamin D deficiency (25OHD < 50 nmol/l) in different age and BMI groups is shown in figure 1 and 2.

Table 1. Characteristics of the study subjects of the FIN-D2D study (n = 2822).

|                | Men                          | Women                       | p   |
|----------------|------------------------------|-----------------------------|-----|
| n (%)          | 1348 (47.8)                  | 1474 (52.2)                 |     |
| Age (years)    | 60.2                         | 59.4                        |     |
| BMI (kg/m²)    | 27.5                         | 27.5                        |     |
| Use of vitamin D supplements (%) | 18.0                       | 37.0                        | <0.0001 |
| Smokers (%)    | 19.6                         | 11.7                        | <0.0001 |
| Use of hormone replacement therapy (%) | 24.8                      | 21.4                        |     |
| Metabolic syndrome (%) | 59.8                       | 54.0                        | 0.002 |
| Waist circumference (cm) | 100.0                      | 90.4                        | 13.3 |<0.0001 |
| HDL cholesterol concentration (mmol/l) | 1.32                       | 1.55                        | 0.34 |<0.0001 |
| Triglyceride concentration (mmol/l) | 1.49                       | 1.28                        | 0.61 |<0.0001 |
| Diastolic blood pressure | 83.0                       | 80.4                        | 9.0  |<0.0001 |
| Systolic blood pressure | 138.4                      | 135.4                       | 18.8 |<0.0001 |
| Fasting glucose (mmol/l) | 6.4                         | 6.0                         | 1.1  |<0.0001 |
| Type 2 diabetes (%) | 20.8                       | 13.3                        | <0.0001 |
| hs-CRP | 2.6                         | 8.0                         | 7.6  |0.32   |

doi:10.1371/journal.pone.0100235.t001
Table 2. 25OHD concentrations in the Finnish population aged 45–74 years.

| Variable                        | Men                                      | Women                                    |
|---------------------------------|------------------------------------------|------------------------------------------|
|                                 | Mean 25OHD (nmol/l) ± SD (n) p-value     | Mean 25OHD (nmol/l) ± SD (n) p-value     |
| All                             | 58.2±16.9 (1348)                         | 57.1±17.3 (1474)                         |
| Age                             |                                          |                                          |
| 45–49 years                     | 54.0±15.3 (193)                          | 52.3±16.4 (221) <0.0001 <0.0001          |
| 50–54 years                     | 55.3±15.2 (198)                          | 55.1±15.5 (261)                          |
| 55–59 years                     | 58.5±17.8 (234)                          | 58.2±18.7 (257)                          |
| 60–64 years                     | 58.0±18.6 (215)                          | 58.9±18.6 (247)                          |
| 65–69 years                     | 61.7±16.9 (275)                          | 58.3±16.4 (282)                          |
| 70–74 years                     | 60.0±15.9 (233)                          | 59.4±17.4 (206)                          |
| Month of sample collection      |                                          |                                          |
| October                         | 61.0±16.9 (559) <0.0001 <0.0001          | 58.9±17.3 (687) 0.001 0.002               |
| November                        | 56.4±16.1 (532)                          | 55.5±17.2 (543)                          |
| December                        | 56.0±17.7 (257)                          | 55.6±17.2 (244)                          |
| BMI                             |                                          |                                          |
| <25 kg/m²                       | 59.7±18.5 (389) 0.04 0.12                 | 60.0±17.0 (518) <0.0001 <0.0001          |
| 25–29.9                         | 58.0±15.9 (664)                          | 58.4±18.7 (553)                          |
| 30–34.9                         | 57.6±17.4 (224)                          | 52.8±14.8 (278)                          |
| >35                             | 53.9±14.4 (70)                           | 48.7±13.1 (124)                          |
| Physical activity               |                                          |                                          |
| Low                             | 53.9±17.8 (267) <0.0001 <0.0001          | 51.8±17.5 (270) <0.0001 <0.0001          |
| Moderate                        | 58.3±15.9 (760)                          | 57.5±16.9 (872)                          |
| High                            | 62.1±17.4 (295)                          | 60.6±17.8 (307)                          |
| Use of vitamin D containing supplements |                                      |                                          |
| No                              | 57.0±16.8 (1105) <0.0001 <0.0001          | 53.9±16.7 (929) <0.0001 <0.0001          |
| Yes                             | 63.9±16.1 (243)                          | 62.5±17.1 (545)                          |
| Smoking                         |                                          |                                          |
| No                              | 59.6±16.3 (1069) 0.0002                   | 57.6±17.3 (1308) 0.002 0.03               |
| Yes                             | 53.2±18.3 (261)                          | 52.9±17.8 (153)                          |
| Use of hormone replacement therapy |                                      |                                          |
| No                              | -                                       | 56.4±17.4 (1016) 0.02 0.48                |
| Yes                             | -                                       | 58.9±17.2 (335)                          |
| Menstruation                    |                                          |                                          |
| No                              | -                                       | 58.0±17.7 (1118) 0.002 0.27               |
| Yes                             | -                                       | 54.4±16.0 (304)                          |
| Educational level               |                                          |                                          |
| 0–9 years                       | 58.2±16.8 (557) 0.32 0.93                 | 57.0±16.6 (507) 0.97 0.63                 |
| 10–12 years                     | 57.4±17.3 (381)                          | 57.2±16.8 (434)                          |
| >13 years                       | 59.2±16.5 (393)                          | 57.2±18.6 (506)                          |
| Total household income          |                                          |                                          |
| <30 000 €/year                 | 57.3±16.5 (529) 0.16 0.28                 | 57.5±17.5 (640) 0.34 0.51                 |
| 30 001–60 000 €/year            | 59.3±16.9 (534)                          | 56.5±17.0 (513)                          |
| 60 001–80 000 or more €/year    | 58.6±15.3 (211)                          | 58.5±18.3 (204)                          |

*adjusted for age, gender, BMI, month of sample collection, physical activity and smoking.

doi:10.1371/journal.pone.0100235.t002
25OHD level in relation to features of MetS and glucose regulation

The association of 25OHD level with MetS, components of MetS and with glucose regulation is presented in table 3. In the univariate analysis the presence of MetS was associated with lower 25OHD level in women (p = 0.0001). Higher waist circumference in women (p = 0.001) and higher triglyceride concentration both in men (p = 0.0007) and in women (p < 0.0001) associated with low 25OHD level. 25OHD level was lower in those women that had hs-CRP concentration higher than 10 mg/l than those that had lower than 10 mg/l (p = 0.04).

In the multivariate model (adjusted for age, gender, BMI, month of sample collection, physical activity, smoking and waist circumference) association of 25OHD level with triglyceride concentration remained statistically significant both in men (p = 0.02) and women (p = 0.001), whereas association with presence of MetS, waist circumference and hs-CRP in women did not. No association between 25OHD and HDL concentration, blood pressure, fasting glucose, type 2 diabetes or glucose regulation was seen in this study.

25OHD level in relation to CVD markers

The association of 25OHD level with CVD markers is shown in figure 3 and 4. No association was found between 25OHD and Framingham score in the univariate analysis (p = 0.67 in men and p = 0.44 in women) or when adjusted for age, gender, BMI, month of sample collection, physical activity and smoking (p = 0.47 in men and p = 0.44 in women). Higher apoB/apoA1 ratio associated with lower 25OHD level in the univariate analysis both in men (p = 0.0005) and in women (p < 0.0001). Association remained statistically significant (p = 0.04 in men and p = 0.03 in women) when adjusted for age, gender, BMI, month of sample collection, physical activity, smoking and waist circumference.
Discussion

In this population-based study representing a relatively large cohort, we analyzed association of 25OHD with several life-style factors and metabolic and cardiovascular disease markers. Our results are mainly consistent with a previous large (n = 5714) Finnish population-based study [27], where samples were collected during year 2000 (during year 2007 in the present study). The mean 25OHD level was higher in our study (58.2 nmol/l in men and 57.1 nmol/l in women) than in the previous study (45.5 nmol/l in men and 45.2 nmol/l in women). The difference may be explained by fortification of liquid dairy products with vitamin D since 2003 in Finland. Furthermore, better awareness of vitamin D deficiency has led to an increase in the use of vitamin D supplements; 10.2% of the participants used vitamin D supplements during year 2000, whereas in the present study 18% of men and 37% of women used vitamin D supplements. Methodological differences in 25OHD analysis in these two studies, however, may complicate reliable comparison of the mean 25OHD level between these two time points.

We found a positive association between 25OHD level and age in our study population aged 45–74 years. The result is somewhat unexpected since an inverse association between 25OHD and age has been shown in several previous large population-based studies [28–30], and since the elderly are thought to be at a special risk of vitamin D deficiency due to diminished outdoor activity, one-sided diet and a decline in the ability of the skin to synthesize vitamin D [28,31]. However, our results are consistent with a study of

| Table 3. Association of 25OHD level with metabolic syndrome, type 2 diabetes and estimated cardiovascular disease risk (Framingham score) in the Finnish population aged 45–74 years. |
|-------------------------------------------------|-----------------------------------|-------------------|-------------------|-----------------------------------|-------------------|
| Metabolic syndrome (ref. 17)                      | Men                               | Women             |
| Mean 25OHD (nmol/l) (n) p-value                  | p-value (adjusted*)               | Mean 25OHD (nmol/l) (n) p-value (adjusted*) |
| No                                               | 58.9±17.6 (540) 0.24              | 57.8±16.4 (804)    | 57.0±17.7 (675) 0.0001 | 55.4±16.9 (793) 0.15 |
| Yes                                              | 57.8±16.4 (804)                  |                   | 57.0±17.7 (675) 0.0001 | 55.4±16.9 (793) 0.15 |
| Metabolic syndrome components                     |                                   |                   |                   |                                   |
| Waist circumference                               |                                   |                   |                   |                                   |
| <94 cm (men); <80 cm (women)                      | 59.0±18.6 (403) 0.34              | 59.9±16.8 (314) 0.001 | 57.5±17.7 (1130) 0.10 | 57.7±16.1 (344) 0.51 |
| >94 cm (men); >80 cm (women)                      | 58.0±16.1 (942)                  |                   | 56.3±17.4 (1155) 0.10 | 55.7±16.1 (344) 0.51 |
| HDL                                              |                                   |                   |                   |                                   |
| >1.0 mmol/l (men); >1.3 mmol/l (women)            | 58.2±17.1 (1181) 0.86              | 57.5±17.7 (1130) 0.10 | 57.7±16.1 (344) 0.51 | 55.7±16.1 (344) 0.51 |
| <1.0 mmol/l (men); <1.3 mmol/l (women)            | 58.4±15.4 (167)                  |                   | 57.7±16.1 (344) 0.51 | 55.7±16.1 (344) 0.51 |
| Triglycerides                                    |                                   |                   |                   |                                   |
| <1.7 mmol/l                                      | 59.1±16.9 (999) 0.0007            | 58.2±17.6 (1203) <0.0001 | 57.7±16.1 (344) 0.51 | 55.7±16.1 (344) 0.51 |
| >1.7 mmol/l                                      | 55.6±16.7 (349)                  |                   | 52.2±15.1 (271) 0.001* | 52.2±15.1 (271) 0.001* |
| Blood pressure                                    |                                   |                   |                   |                                   |
| Systolic<130 and/or diastolic<85 mm Hg            | 58.8±16.2 (341) 0.48              | 58.0±17.6 (458) 0.15 | 56.6±17.2 (1014) 0.06 | 56.6±17.2 (1014) 0.06 |
| Systolic>130 and/or diastolic>85 mm Hg            | 58.1±17.1 (1006)                 |                   | 56.6±17.2 (1014) 0.06 | 56.6±17.2 (1014) 0.06 |
| Fasting glucose                                   |                                   |                   |                   |                                   |
| <5.6 mmol/l                                       | 58.6±17.6 (164) 0.79              | 58.3±17.9 (451) 0.08 | 56.6±17.1 (1023) 0.67 | 56.6±17.1 (1023) 0.67 |
| >5.6 mmol/l                                       | 58.2±16.8 (1184)                 |                   | 56.6±17.1 (1023) 0.67 | 56.6±17.1 (1023) 0.67 |
| Glucose regulation                                |                                   |                   |                   |                                   |
| Normal glucose regulation (NGR)                   | 58.6±16.9 (479) 0.97              | 58.3±17.8 (813) 0.07 | 56.6±18.3 (71) 0.22 | 56.6±18.3 (71) 0.22 |
| Type 2 diabetes (known and screen-detected together) | 58.0±14.0 (104)                  |                   | 55.8±16.2 (123) 0.07 | 55.8±16.2 (123) 0.07 |
| Screen-detected diabetes mellitus (SDM)           | 57.5±18.4 (173)                  |                   | 55.8±16.2 (123) 0.07 | 55.8±16.2 (123) 0.07 |
| Impaired glucose tolerance (IGT)                  | 58.5±16.2 (241)                  |                   | 55.2±16.1 (260) 0.02 | 55.2±16.1 (260) 0.02 |
| Impaired fasting glucose (IFG)                    | 58.4±17.5 (337)                  |                   | 55.7±17.5 (188) 0.03 | 55.7±17.5 (188) 0.03 |
| hs-CRP                                            |                                   |                   |                   |                                   |
| <10 mg/l                                          | 58.3±16.8 (1314) 0.75             | 57.3±17.4 (1417) 0.04 | 52.5±15.9 (57) 0.93 | 52.5±15.9 (57) 0.93 |
| >10 mg/l                                          | 57.3±20.2 (34)                   |                   | 57.3±17.4 (1417) 0.04 | 52.5±15.9 (57) 0.93 |

*adjusted for age, gender, BMI, month of sample collection, physical activity and smoking.

**adjusted for age, gender, BMI, month of sample collection, physical activity, smoking and waist circumference.

doi:10.1371/journal.pone.0100235.t003
Ja¨a¨skeläinen et al. [27], where a positive association between 25OHD and age was seen in Finnish population aged 30–79 years. Among Finnish people, the average retirement age was 60 years when the study was done. People aged 60–74 years could thus be regarded as “active pensioners”, still quite healthy and spending time travelling abroad and in the home country. It is typical for Finnish pensioners to spend time at the summer cottages were outdoor living is usual. Eating fish is also more common among older than younger Finns [2]. It is thus possible that older Finns get more vitamin D from the diet and also from the sun by spending more time outdoors and by travelling, which is mirrored by higher 25OHD level of the older Finns all year round. However, since this study was restricted to people aged 74 years or less, and the study of Ja¨a¨skeläinen et al. [27] to people aged 79 years or less, it cannot be determined if the positive association of 25OHD with age remains in the elderly aged 80 years or more.

In this study we found an inverse association between 25OHD level and BMI. Association of low 25OHD level and obesity has been seen in several studies [32–34]. It is likely that higher BMI leads to lower 25OHD level, whereas lower 25OHD is unlikely to have an effect on BMI [35]. It is not known whether low 25OHD level is due to for example changes in vitamin D metabolism in obese individuals or life style factors associated with obesity, for example low sun light exposure. It is known that 25OHD is stored in adipose tissue and muscle [36]. It is possible that bioavailability of 25OHD or its precursors stored in adipose tissue is poor [36]. Recently it has been suggested that muscle provides an extravascular pool through which 25OHD circulates [37,38]. This could explain the positive association between physical activity and 25OHD level found in this study. Also previously, high 25OHD level have been positively associated with outdoor activity [27,39,40] and indoor exercise [41]. 25OHD level is known to associate with muscle strength and function [42,43]. Low vitamin D status associates with poorer physical performance and a greater decline in physical performance and increases the risk of falls at least in the elderly [44,45].

The present study confirms that smoking is an independent lifestyle factor associated with low 25OHD level both in men and women. Also previously it has been shown that low 25OHD level is associated with smoking [27,46,47] and smoking related cancers [48]. It is not known whether the inverse association between 25OHD level and smoking is due to life-style factors not accessed in this study (for example diet). It has been suggested though that chemicals in tobacco smoke may have a direct effect on vitamin D metabolism and function [46]. There is evidence that smoking alters expression of several genes, among which are some genes acting in the metabolic pathway of vitamin D [46,49]. Low-grade chronic inflammation has been associated with low 25OHD level [50] and smoking increases inflammation [51]. There may be a benefit in increasing vitamin D supplementation among smokers,
References

1. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–81.
2. The National Findiet 2007 Survey. Kansanterveyslaitoksen julkaisuja B 23/2008.
3. Frohlich MN, Patel AS (2010) Update in pediatrics: focus on fat-soluble vitamins. Nutr Clin Pract 25(4):340–4.
4. Nordic Council of Ministers (2004) Nordic nutrition recommendations 2004. Integrating nutrition and physical activity. Aarhus, Denmark: Nordic Council of Ministers.
5. UK Department of Health (1998) Nutrition and bone health: with particular reference to calcium and vitamin D. Report on health and social subjects (49). London, United Kingdom: The Stationary Office.
6. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84(1):18–28.
7. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, Yetley EA, Looker AC, et al. (2013) Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the U.S. nationally representative NHANES. J Clin Endocrinol Metab 98(7):3001–9.
8. Lukxuvolda MF, Kuijpers RS, Kema IP, Dijkhuis DA, Mushket FA (2012) Traditionally living populations in East Africa have a mean serum 25-OH vitamin D level of 115 nmol/l. Br J Nutr 108(9):1557–61.
9. Jones G (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88(2):509–510.
10. Hathcock JN, Shao A, Vieth R, Heaney R (2007) Risk assessment for vitamin D. Am J Clin Nutr 85(6):16–18.
11. Austin MA, King MC, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82(2):495–506.
12. Risso M, Perucchi A, Fraschini A, Di Lorenzo G, Rini GB, et al. (2009) Small dense low-density lipoproteins (LDL) are predictors of cardio- and cerebrovascular events in subjects with the metabolic syndrome. Clin Endocrinol (Oxf) 70(6):870–5.
13. Scanni AM, Edelstein C (2008) HDL: bridging past and present with a look at the future. FASEB J 22(12):4044–54.
14. Prasad R, Laggner P (2009) Molecular structure of low density lipoprotein: current status and future challenges. Eur Biophys J 38(5):435–50.
15. Wallentin K, Bokemark L, Wikstrand J, Holte J, Fagerberg B (2004) Apolipoprotein B/apolipoprotein A-I ratio in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35(10):2185–92.
16. Raitakari OT, Makkonen VP, McQueen MJ, Nieni J, Juonala M, et al. (2013) Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. Atherosclerosis 226(1):245–51.
17. McQueen MJ, Hawken S, Wang X, Oumpuu S, Sniderman A, et al. (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries [the INTERHEART study]: a case-control study. Lancet 372(9634):224–33.
18. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, et al. (2009) Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 30(6):710–17.
19. Juonala M, Väinik J, Kahonen M, Solakivi T, Helenius H, et al. (2008) Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. J Am Coll Cardiol 52(4):293–9.
20. Hyppönen E, Boucher BJ, Berry DJ, Power C (2003) 25-hydroxyvitamin D, IGF-I, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British birth cohort. Diabetes 52(7):298–305.
21. Kayanil S, Harris SB, Retnakaran R, Vieth R, King JA, et al. (2013) Prospective association of 25(OH)D with metabolic syndrome. Clin Endocrinol (Oxf) 80(4):502–7.
22. Saaristo T, Pitlonen M, Keinanen-Kiukaanniemi S, Vanhala M, Saltevo J, et al. (2007) National type 2 diabetes prevention programme in Finland: FIN-D2D. J Cardiovasc Risk 14(3):161–74.
23. Saaristo T, Molanen L, Koepi-Hyövölä E, Vanhala M, Saltevo J, et al. (2010) Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care 33(10):2146–51.
24. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1645–9.
25. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva, World Health Organization.
26. Anderson KM, Wilson PWF, Odell PM, Kannell WB (1991) An updated coronary risk profile: a statement for health professionals. Circulation 83:357–363.
27. Jakseltenain K, Kneck P, Marmienn J, Særes-Jaske I, Mannisto S, et al. (2013) Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health. Eur J Nutr 52(2):315–23.
28. Jorde R, Steue M, Enasun N, Figenschau Y, Grimes G (2010) Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromso study. Eur J Nutr 49(7):401–7.
29. Melamed ME, Michos ED, Post W, Ateor B (2008) 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168(15):1629–37.
30. Zittermann A, Ernst JB, Gunnett JB, Borgermann J (2014) Vitamin D supplementation, body weight and human serum 25-hydroxyvitamin D response: a systematic review. Eur J Nutr 2014 Mar;53(2):367–74.
31. MacLaughlin J, Holick MF (1983) Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 74(6):1536–8.
32. Liel Y, Ulmer E, Shary J, Holllis BW, Bell NH (1988) Low circulating vitamin D in obesity. Calcif Tissue Int 43:199–201.
33. McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD (2008) Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 7:4–8.
34. Wartman J, Matsouka LY, Chen TC, Lu Z, Holick MF (2000) Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72:690–3.
35. Vimeswaran K, Berry D, Lu C, Pils S, Hiraki L, et al. (2011) Causal relationship between obesity and vitamin D status: Bi-directional mendelian randomization analysis of multiple cohorts. PLoS Med 10:1549–1676.
36. Heaney RP, Horst RL, Cullen DM (2009) Armas LA. Vitamin D and obesity. Calcif Tissue Int 85:199–203.
37. McGill AT, Stewart JM, Litherland FE, Strik CM, Poppitt SD (2008) Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 7:4–8.
38. Pittahaugus P, Mosey AV, Bux toes-Hazsya S, Frisk PB (2010) Maternal smoking and fetal sex significantly affect metabolic enzyme expression in the human fetal liver. J Clin Endocrinol Metab 96:2581–60.
39. Hypponen E, Berry D, Cortina-Borja M, Power C (2010) 25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hematostatic markers: a cross sectional analysis in the 1958 British Birth Cohort. PLoS One 4(3):e5801.
40. Brody JS (2012) Transcriptional alterations induced by cigarette smoke. Int J Cancer 131:12(2):2734–62.
41. Barke F, Takashi T, Koof G, Gysemans C, Mathieu C (2016) Vitamin D: modulator of the immune system. Curr Opin Pharmacol 10(4):482–96.
42. Gillott X, Seemano L, Saeidenberg-Kermanich N, Falgarone G, Boissier MC (2010) Vitamin D and inflammation. Joint Bone Spine 77(6):552–7.
43. Penna G, Grandin I (2000) 1 Alpha,24-dihydroxyvitamin D3 inhibits cell-mediated immunity and suppresses cell-mediated immunity and suppresses the development of autoimmunity. J Immunol 165(4):2277–83.
44. Scragg R, Holdaway I, Jackson R, Lim T (2012) Plasma 25-hydroxyvitamin D and Risk of Tobacco-Related Disease. J Steroid Biochem Mol Biol 103:786–792.
45. Baeke F, Takiishi T, Koof G, Gysemans C, Mathieu C (2010) Vitamin D: modulator of the immune system. Curr Opin Pharmacol 10(4):482–96.
46. Guillot X, Seemano L, Saeidenberg-Kermanich N, Falgarone G, Boissier MC (2010) Vitamin D and inflammation. Joint Bone Spine 77(6):552–7.
47. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, et al. (2007) An analysis of multiple cohorts. PLoS Med 10:1549–1676.
48. Wittum TE, Wei C, Heelan RF, Mora S, Selhub J, et al. (2013) Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 98(10):E1817–23.
49. Brot C, Jorgensen NR, Sorensen OH (1999) The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr 53(12):920–6.
50. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Hataja R, et al. (2007) An analysis of serum vitamin D concentrations <40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr 86(3):714–7.
51. Afzal S, Bojesen SE, Nordestgaard BG (2013) Low Plasma 25-Hydroxyvitamin D and Risk of Tobacco-Related Cancer. Clin Chem 59(3):771–80.
52. Baeke F, Takiishi T, Koof G, Gysemans C, Mathieu C (2010) Vitamin D: modulator of the immune system. Curr Opin Pharmacol 10(4):482–96.
53. Guillot X, Seemano L, Saeidenberg-Kermanich N, Falgarone G, Boissier MC (2010) Vitamin D and inflammation. Joint Bone Spine 77(6):552–7.